TITLE

Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Tablets (Complera)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
September 2011
SOURCE
Internal Medicine Alert;9/15/2011, Vol. 33 Issue 17, p133
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the emtricitabine/rilpivirine/tenofovir disoproxil fumarate drug combination known as Complera for the treatment of HIV-1 infection, developed by Gilead Sciences Inc.
ACCESSION #
66179454

 

Related Articles

  • The New Little Blue Sex Pill. HEYWOOD, TODD // Between the Lines (10807551);5/22/2014, Issue 2221, p5 

    The article offers information on an anti-HIV drug that was developed by Gilead called Truvada.

  • Gilead's Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide Meets Primary 48-Week Objective in Phase 3 Study.  // Clinical Infectious Diseases;11/15/2015, Vol. 61 Issue 10, pii 

    The article discusses a phase 3 study by the biotechnology firm Gilead Sciences Inc. to evaluate the efficacy of a fixed-dose combination of emtricitabine and tenofovir alafenamide for the treatment of HIV-1 infection, which showed virologic suppression rate same as tenofovir disoproxil fumarate.

  • New quad pill for HIV. Tanzi, Maria G. // Pharmacy Today;Oct2012, Vol. 18 Issue 10, p45 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the tablet,Stribild from Gilead Sciences Inc., that contains elvitegravir, cohicistat, emtricitabine, tenofovir, used for the management of HIV-1 infection in the U.S. It mentions that the approval of the pills are...

  • Solution-based treatment approach to replace 'multiple shots on goal'? Bogg, Jennifer // BioWorld Today;2/11/2014, Vol. 25 Issue 28, p1 

    The article focuses on the trend towards solution-based or combination treatment approach noted as having more potential for success than the "multiple shots on goal" strategy. Highlighted are biopharmaceuticals adopting solutions-based approach which include Gilead Sciences Inc. with its HIV...

  • Complera Nod Bridges Gilead's HIV Franchise; All Eyes on Quad. Boggs, Jennifer // BioWorld Today;8/12/2011, Vol. 22 Issue 156, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) approved Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) formulation from Gilead Sciences Inc. Information on Complera is given, including its price. Gilead also reported that is has favorable arrangement...

  • Potential HIV prophylaxis enters Canadian pilot trial. Lawson, Jack // CMAJ: Canadian Medical Association Journal;5/13/2014, Vol. 186 Issue 8, pE234 

    The article focuses on the clinical trials of Truvada for the treatment of HIV that will begin in Canada in March 2015. Topics covered include the failure of Gilead Sciences Canada, Inc. to submit an application to Health Canada for the use of Truvada as prophylaxis, an overview of the pilot...

  • IS THIS THE NEW CONDOM? MURPHY, TIM // Out;Oct2013, Vol. 22 Issue 3, p70 

    The article focuses on Truvada, a pre-exposure HIV prophylaxis (PrEP), from biotechnology company Gilead. The pill has been approved by the U.S. Food and Drug Administration and is covered by health insurers, making reference to findings from a 2010 study of HIV-negative gay men called iPrex. It...

  • A HIV shot could replace pills. Investor's Business Daily // Investors Business Daily;3/11/2014, pA02 

    Daily pills like

  • Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla(r) in Pivotal Phase 3 Study.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article offers information on an announcement made by Gilead Sciences Inc., biopharmaceutical company regarding its study related to the clinical trials of Quad, for treatment against HIV-1 infection which revealed that drug is equally effective as Atripla, most-prescribed HIV treatment...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics